A Phase 4 interventional study of EMPA/LINA 10/5 mg QD (n=22) and LINA/EMPA 5/10 mg QD (N=22) in Type2 Diabetes, sponsored by M.H.H. Kramer. Status unknown at 1 site in Netherlands. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-14.
Sponsored by M.H.H. Kramer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 73rd largest by enrollment, is one of 14 that started in 2017, is one of 50 in phase 4, and was the 59th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Celltrion · Sites in Korea, Republic of
Ages 19+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 14 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 79 across the 130 interventional studies. Of the 91 that completed or were terminated, 38 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 130 have an industry lead sponsor. The 10 most frequent:
M.H.H. Kramer is the lead sponsor of 2 studies on the registry; none are open to participants now.
M.H.H. Kramer has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
10 of the studies testing empagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT05960656The University of Texas Health Science Center at San AntonioSGLTi, Hepatic Glucose Production and Ketogenesis | 2027-06-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on renal physiology and biomarkers in metformin-treated T2DM patients.
Sodium-glucose linked transporters (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively novel glucose-lowering drugs for the treatment of T2DM. These agents seem to exert pleiotropic actions 'beyond glucose control'. SGLT-2 inhibitors decrease proximal sodium reabsorption and decrease glomerular pressure and albuminuria in rodents and type 1 diabetes patients. In addition, SGLT-2 inhibitors reduce, blood pressure and body weight. In rodents, SGLT-2 inhibitors also improved histopathological abnormalities associated with DKD. DPP-4 inhibitors are considered weight neutral, improve lipid profiles and slight reductions in blood pressure have been reported. To date, the potential renoprotective effects and mechanisms of SGLT-2 inhibitors and combination therapy with SGLT-2 inhibitors have not been sufficiently detailed in human type 2 diabetes. The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with an SGLT-2 inhibitor and a DPP-4 inhibitor on renal physiology and biomarkers in metformin-treated T2DM patients.
66 patients with type 2 diabetes will undergo a 16-week intervention period with 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, followed by 8-week empagliflozin and linagliptin (DPP-4 inhibitor) combination therapy or 8-week linagliptin monotherapy, followed by 8-week linagliptin and empagliflozin combination therapy or 8-week gliclazide (SU derivative), followed by 8-week gliclazide intensification therapy in order to assess changes in the outcome parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Written
Exclusion Criteria:
Recent (\<6 months) history of cardiovascular disease, including
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)
Drug: EMPA/LINA 10/5 mg QD (n=22) · Drug: LINA/EMPA 5/10 mg QD (N=22)
8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)
Drug: EMPA/LINA 10/5 mg QD (n=22) · Drug: LINA/EMPA 5/10 mg QD (N=22)
8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)
Drug: Gliclazide 30 mg QD/BID (N=22)
Drug page: Empagliflozin
Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
Also known as: Jardiance, Tradjenta
Drug page: Linagliptin
Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
Also known as: Tradjenta, Jardiance
Drug page: Gliclazide
Once daily or twice daily treatment with oral glicazide MR 30mg
Also known as: Gliclazide Sandoz
GFR
Changes from baseline following 16-week treatment on renal hemodynamics in both the fasting and postprandial state, measured as GFR (determined by the inulin-clearance technique)
Time frame: 16 weeks
GFR
Changes from baseline following 8-week treatment on renal hemodynamics in both the fasting and postprandial state, measured as GFR (determined by the inulin-clearance technique)
Time frame: 8 weeks
Renal tubular function
24-hour urine sodium-, potassium-, chloride-, calcium-, magnesium-, phosphate-, uric acid-, bicarbonate-, ammonium-, urea- and glucose excretion, urine osmolality and urinary pH
Time frame: 16 weeks
Renal tubular function
24-hour urine sodium-, potassium-, chloride-, calcium-, magnesium-, phosphate-, uric acid-, bicarbonate-, ammonium-, urea- and glucose excretion, urine osmolality and urinary pH
Time frame: 8 weeks
Renal Damage
24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)
Time frame: 16 weeks
Renal Damage
24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)
Time frame: 10 weeks
Renal Damage
24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)
Time frame: 8 weeks
Renal Damage
24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)
Time frame: 2 weeks
Heart Rate (Dinamap®)
Measured using an automated oscillometric blood pressure device (Dinamap®)
Time frame: 16 weeks
Heart Rate (Dinamap®)
Measured using an automated oscillometric blood pressure device (Dinamap®)
Time frame: 10 weeks
Heart Rate (Dinamap®)
Measured using an automated oscillometric blood pressure device (Dinamap®)
Time frame: 8 weeks
Heart Rate (Dinamap®)
Measured using an automated oscillometric blood pressure device (Dinamap®)
Time frame: 2 weeks
Blood Pressure (Dinamap®)
Measured using an automated oscillometric blood pressure device (Dinamap®)
Time frame: 16 weeks
Blood Pressure (Dinamap®)
Measured using an automated oscillometric blood pressure device (Dinamap®)
Time frame: 10 weeks
Blood Pressure (Dinamap®)
Measured using an automated oscillometric blood pressure device (Dinamap®)
Time frame: 8 weeks
Blood Pressure (Dinamap®)
Measured using an automated oscillometric blood pressure device (Dinamap®)
Time frame: 2 weeks
Body anthropometrics: Body mass index
Body mass index
Time frame: 16 weeks
Body anthropometrics: Body mass index
Body mass index
Time frame: 8 weeks
Body anthropometrics: Body weight
Body weight
Time frame: 16 weeks
Body anthropometrics: Body weight
Body weight
Time frame: 8 weeks
Body anthropometrics: Height
Height
Time frame: 16 weeks
Body anthropometrics: Height
Height
Time frame: 8 weeks
Body anthropometrics: Waist circumference
Waist circumference
Time frame: 16 weeks
Body anthropometrics: Waist circumference
Waist circumference
Time frame: 8 weeks
Body anthropometrics: Hip circumference
Hip circumference
Time frame: 16 weeks
Body anthropometrics: Hip circumference
Hip circumference
Time frame: 8 weeks
Body fat content
Body fat content by bioimpedance analysis
Time frame: 16 weeks
Body fat content
Body fat content by bioimpedance analysis
Time frame: 8 weeks
Blood pressure (NexFin®)
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 16 weeks
Blood pressure (NexFin®)
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 8 weeks
Heart Rate (NexFin®)
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 16 weeks
Heart Rate (NexFin®)
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 8 weeks
Stroke Volume
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 16 weeks
Stroke Volume
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 8 weeks
Cardiac output
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 16 weeks
Cardiac output
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 8 weeks
Cardiac index
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 16 weeks
Cardiac index
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 8 weeks
Total systemic vascular resistance
Continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 16 weeks
Total systemic vascular resistance
Continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 8 weeks
Cardiac autonomic nervous system function
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 16 weeks
Cardiac autonomic nervous system function
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 8 weeks
Microvascular function
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 16 weeks
Microvascular function
Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)
Time frame: 8 weeks
Arterial stiffness
Assessed by radial artery applanation tonometry (SphygmoCor®)
Time frame: 16 weeks
Arterial stiffness
Assessed by radial artery applanation tonometry (SphygmoCor®)
Time frame: 8 weeks
Insulin sensitivity (M-value)
Derived from the glucose infusion rate during the euglycemic clamp (M-value)
Time frame: 16 weeks
Insulin sensitivity (M-value)
Derived from the glucose infusion rate during the euglycemic clamp (M-value)
Time frame: 8 weeks
Insulin sensitivity (OGIS)
Meal tolerance test (OGIS)
Time frame: 16 weeks
Insulin sensitivity (OGIS)
Meal tolerance test (OGIS)
Time frame: 8 weeks
Insulin sensitivity (Matsuda index)
Meal tolerance test (Matsuda index)
Time frame: 16 weeks
Insulin sensitivity (Matsuda index)
Meal tolerance test (Matsuda index)
Time frame: 8 weeks
Beta-cell function (insulinogenic index)
Meal tolerance test (insulinogenic index)
Time frame: 16 weeks
Beta-cell function (insulinogenic index)
Meal tolerance test (insulinogenic index)
Time frame: 8 weeks
Beta-cell function (HOMA-B)
HOMA-B
Time frame: 16 weeks
Beta-cell function (HOMA-B)
HOMA-B
Time frame: 8 weeks
Beta-cell function (ratio of postprandial glucose and C-peptide)
Meal tolerance test (ratio of postprandial glucose and C-peptide)
Time frame: 16 weeks
Beta-cell function (ratio of postprandial glucose and C-peptide)
Meal tolerance test (ratio of postprandial glucose and C-peptide)
Time frame: 8 weeks
Lipid spectrum
(triglycerides (TG), total-cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)
Time frame: 16 weeks
Lipid spectrum
(triglycerides (TG), total-cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)
Time frame: 8 weeks
DPP-4
DPP-4 activity
Time frame: 16 weeks
DPP-4
DPP-4 activity
Time frame: 8 weeks
ACE
ACE activity
Time frame: 16 weeks
ACE
ACE activity
Time frame: 8 weeks
HbA1c (%)
HbA1c (%)
Time frame: 16 weeks
HbA1c (%)
HbA1c (%)
Time frame: 8 weeks
Fasting plasma glucose (mmol/L)
Fasting plasma glucose (mmol/L)
Time frame: 16 weeks
Fasting plasma glucose (mmol/L)
Fasting plasma glucose (mmol/L)
Time frame: 8 weeks
Postprandial plasma glucose (mmol/L)
Postprandial plasma glucose (mmol/L)
Time frame: 16 weeks
Postprandial plasma glucose (mmol/L)
Postprandial plasma glucose (mmol/L)
Time frame: 8 weeks
Free Fatty Acids (FFA) (mmol/L)
Free Fatty Acids (FFA) (mmol/L)
Time frame: 16 weeks
Free Fatty Acids (FFA) (mmol/L)
Free Fatty Acids (FFA) (mmol/L)
Time frame: 8 weeks
Insulin (mg/L)
Insulin (mg/L)
Time frame: 16 weeks
Insulin (mg/L)
Insulin (mg/L)
Time frame: 8 weeks
Glucagon (mg/L)
Glucagon (mg/L)
Time frame: 16 weeks
Glucagon (mg/L)
Glucagon (mg/L)
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2017 to primary completion in Jun 2021, 42 months.
Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 42 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Linagliptin · Gliclazide
M.H.H. Kramer